Search company, investor...

Radiation Shield Technologies

About Radiation Shield Technologies

Radiation Shield Technologies (RST) is the world leader in the research, design and production of personal protection systems for ionizing and nuclear radiation. The company's core technology, DemronTM , is specifically engineered to combine radiation protection with "ease of use" in order to maximize effective radiological defense. RST's primary goal is to ensure that all DemronTM products are of the highest protective quality. This is achieved by working closely with the company's end users, developing new standards of personal radiation protection, and meeting the specific needs of those groups most at risk of exposure. After almost a decade of development, RST is proud to introduce DemronTM to the industries, governments and everyday people who, until now, have had no options for true personal radiation protection.n

Headquarters Location

Radiation Shield Technologies Corporate Office 1825 Ponce De Leon Blvd #456

Coral Gables, Florida, 33134,

United States

Missing: Radiation Shield Technologies's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Radiation Shield Technologies's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest Radiation Shield Technologies News

Demron, the Only Anti Nuclear, Anti Radiation Personal Protective Equipment (PPE) by Radiation Shield Technologies (RST)

Mar 9, 2022

News provided by Share this article Share this article MIAMI, March 8, 2022 /PRNewswire/ -- Demron by Radiation Shield Technologies (RST) is the only true anti-nuclear garment that protects against ionizing radiation, chemical, biological agents, and heat stress. Other suits claim to be antinuclear however they only block alpha particles which any fabric can do. No other personal protective equipment (PPE) garment on the market truly reduce exposure to gamma X and high energy beta ionizing radiation. This is proven in multiple Labs, Universities, independent labs and in the field of Fukushima clean up.

Radiation Shield Technologies Frequently Asked Questions (FAQ)

  • Where is Radiation Shield Technologies's headquarters?

    Radiation Shield Technologies's headquarters is located at Radiation Shield Technologies Corporate Office, Coral Gables.

  • Who are Radiation Shield Technologies's competitors?

    Competitors of Radiation Shield Technologies include CivaTech Oncology, Augmenix, Pharmacyclics, Proterixbio, Gold Standard Diagnostics and 12 more.

Compare Radiation Shield Technologies to Competitors

Calpyso Medical

Calypso Medical provides technologies in the radiation oncology market

Xoft Microtube

Xoft is engaged in the practice of radiation oncology through electronic brachytherapy with its miniaturized x-ray tube technology. It's first product, the Axxent Electronic Brachytherapy System applies radiation directly to a tumor bed within the body without the use of radioactive isotopes, heavy shielding, or major capital equipment.


i-Nalysis builds and sells a palm-sized X-ray Fluorescence (XRF) unit.

BioMicro Systems

BioMicro Systems was founded in 2000 to develop and improve microfluidic microarray sample processing. Microarrays are tools used by major pharmaceutical companies and research laboratories to sift through and analyze information contained within a genome. A microarray consists of different nucleic acid probes that are chemically attached to a substrate, which can be a microchip, a glass slide or microsphere-sized beads. In 2003 BioMicro Systems launched the MAUI Hybridization System, a cutting-edge microarray instrument, designed to target the processing bottleneck encountered during the critical hybridization step in gene expression studies.

Nanoprobes Logo

Nanoprobes was founded to develop the most sensitive reagents and technology for detecting biological molecules. The company's gold labeling technology uses chemically cross-linked metal clusters and nanoparticles as labels. Unlike conventional immunogold probes, in which colloidal gold particles are electrostatically adsorbed to antibodies and proteins, the company's gold labels are uncharged molecules which are cross-linked to specific sites on biomolecules. This aims to give the company's probes a range and versatility which is not available with colloidal gold. The company's labels can be attached to any molecule with a reactive group -- proteins, peptides, oligonucleotides, small molecules and lipids -- for detection and localization. Other labels can be combined with the company's gold labels; the company's FluoroNanogold probes combine Nanogold and fluorescein into a single probe for imaging a specimen both by fluorescence and electron microscopy. New probes can be engineered based on any fragment of a naturally occurring biomolecule, and the label can be positioned away from the binding site so it does not interfere with binding. The company's 1.4 nm Nanogold probes have been cited in over 80 publications, and the company are now developing larger cross-linkable labels in order to offer the company's customers larger covalently linkable probes with the same advantages.

LUX biotechnology

LUX biotechnology (LUX) develops and distributes high quality calibration tools and reagents for luminescence and fluorescence applications.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.